Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Andrew Fein reiterates Syros Pharmaceuticals (NASDAQ:SYRS) with a Buy and maintains $15 pric...
Syros Pharmaceuticals (NASDAQ:SYRS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of...
U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 0.4% on Tuesday. The Dow traded down 0...
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter esti...
Piper Sandler analyst Edward Tenthoff reiterates Syros Pharmaceuticals (NASDAQ:SYRS) with a Overweight and maintains $13 pri...
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
HC Wainwright & Co. analyst Andrew Fein reiterates Syros Pharmaceuticals (NASDAQ:SYRS) with a Buy and maintains $15 pric...
